LINFOMA ESPLENICO DE LA ZONA MARGINAL PDF
Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.
|Published (Last):||4 May 2015|
|PDF File Size:||9.50 Mb|
|ePub File Size:||13.16 Mb|
|Price:||Free* [*Free Regsitration Required]|
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. How esplenici decide when a neonate needs a transfusion.
One out of the three partial responders have a persistent response. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Our data show that pentostatin administered every other week has a good epslenico of activity in the treatment of SMZL and suggest that this schedule could be considered a possible therapeutic option for patients who are not fit for splenectomy or have relapsed.
September 27, Conflict of interest: BCL10 expression in normal and neoplastic lymphoid tissue.
The aim of any lymphoma classification is to provide an international language allowing communication. CD 5- CD 10Otros: The mediastinal mass and lymphadenopathy recurred.
Considering the lack of established data regarding this rare and clinically challenging issue, we made a systematic search for indexed articles published on this topic. The indications for treatment were the same as those used for patients with chronic lymphocytic leukemia. September 21, Accepted: Pemphigus Vegetans in the Inguinal Folds.
LEZM – Linfoma Esplénico de la Zona Marginal
Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. Cell cycle deregulation in B-cell lymphomas.
Hay algunos casos con t 11;14 pero el punto de ruptura es diferente al linfoma del manto. Because of the ljnfoma of the disease, there is no established standard therapy.
This time, an inguinal mass was palpable.
RT PCR para t 11; New approach to classifying non-Hodgkin’s lymphomas: Primary nodal marginal zone lymphomas of splenic and MALT type. Rituximab treatments resulted in longer survival and FFS compared with chemotherapy.
From these cases, it can be suggested that postponement of cytotoxic treatments may be possible in at least some situations.
Health care resources for this disease Expert centres Diagnostic tests 59 Patient organisations 45 Orphan drug s The way in which cases of recurrence of splenic marginal zone lymphoma after splenectomy should be managed is still not fully established. Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma. Para el 20 zoona febrero – Haverford Township School District. Am J Surg Pathol.
No existen datos que justifiquen reconocer esta variante como una enfermedad diferente.
Treatment toxicity, mostly hematological, proved manageable. Splenic lymphoma with villous lymphocytes: Progression to large B-cell lymphoma in splenic marginal zone lymphoma: The current WHO classification of lymphoid neoplasms represents a major step forward in our understanding of these tumours.
Translocation t 11;14 q13;q32 in lx lymphoid disorders. CiteScore measures average citations received per document published.
Catovsky D, Matutes E. Outcomes linfkma patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Linfoma esplénico de la zona marginal:
The classification must be reproducible and clinically relevant, and sufficiently flexible to permit the incorporation of new data. Valorar profilaxis con fluconazol mg po. From our search in the PubMed database using the terms ” rituximab AND marginal zone B cell lymphoma AND therapy”, we found papers, of which six were related to the current topic.
Finally, the classification must be histopathologically based because it is the pathologist who, in most instances, makes the initial diagnosis.